A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of one dose of imeglimin versus placebo after 18 weeks of treatment in subjects with type 2 diabetes mellitus

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of one dose of imeglimin versus placebo after 18 weeks of treatment in subjects with type 2 diabetes mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2015

At a glance

  • Drugs Imeglimin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Poxel
  • Most Recent Events

    • 23 Nov 2015 Results were presented at the World Congress on Insulin Resistance and Cardiovascular Diseases 2015, according to a Poxel media release.
    • 07 Oct 2015 Additional data will be presented at the World Congress on Insulin Resistance and Cardiovascular Diseases in November, as per Poxel media release.
    • 04 Jun 2015 Results published in the Poxel Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top